SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:
Dr. Hung will provide an overview of Medivation and its clinical development programs including dimebon (latrepirdine) for Alzheimer’s and Huntington diseases and MDV3100 for prostate cancer.
A live audio webcast of each presentation will be available on the “Events and Presentations” page of the “Investor Relations” section of the Company’s website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer’s and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer’s medications in patients with mild, moderate and severe Alzheimer’s disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.
SOURCE Medivation, Inc.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,
+1-415-829-4101, or Nicole Foderaro of WeissComm Partners, +1-415-946-1058,
for Medivation, Inc.
